成人低级别胶质瘤T2-FLAIR不匹配征与IDH突变状态的影像基因组学关联:一项更新的系统综述与荟萃分析
该系统综述与荟萃分析纳入14项研究共1986例成人低级别胶质瘤患者,评估T2-FLAIR不匹配征诊断IDH突变的准确性。该征象对IDH突变非共缺失型汇总特异度为99%、敏感度为42%,对任意IDH突变汇总特异度为99%、敏感度为29%,对IDH突变共缺失型敏感度仅1%、特异度69%,为不敏感但高度特异的影像标志物。
要点
- T2-FLAIR不匹配征对IDH突变非共缺失型低级别胶质瘤特异度高达99%,但敏感度仅42%。
- 该征象对IDH突变共缺失型敏感度仅1%,不适用于提示该分子亚型。
- 该征象为不敏感但高度特异的无创影像生物标志物,可能用于筛选IDH突变低级别胶质瘤患者。
核心结论
- T2-FLAIR不匹配征是IDH突变非共缺失型和任意IDH突变低级别胶质瘤的不敏感但高度特异标志物,而对IDH突变共缺失型低级别胶质瘤不是有用标志物。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南,检索PubMed、Embase和Cochrane Library数据库截至2021年4月13日的文献,最终纳入14项研究共1986例成人低级别胶质瘤患者,评估T2-FLAIR不匹配征诊断IDH突变的准确性。
关键影像表现/征象
- T2-FLAIR不匹配征定义为T2高信号病灶在FLAIR上呈低信号,仅边缘呈高信号。
诊断标准与关键数值
- IDH突变共缺失型:汇总AUC 0.46(95%CI 0.42-0.50),敏感度1%(95%CI 0-7%),特异度69%(95%CI 62-75%)。
- IDH突变非共缺失型:汇总AUC 0.75(95%CI 0.71-0.79),敏感度42%(95%CI 34-50%),特异度99%(95%CI 96-100%)。
- 任意IDH突变(不论1p/19q共缺失状态):汇总AUC 0.77(95%CI 0.73-0.80),敏感度29%(95%CI 21-40%),特异度99%(95%CI 92-100%)。
临床应用与阅片要点
- 作者认为该征象可能作为无创影像生物标志物用于筛选IDH突变低级别胶质瘤患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To reveal a radiogenomic correlation between the presence of the T2-fluid-attenuated inversion recovery resection (T2-FLAIR) mismatch sign on MR images and isocitrate dehydrogenase (IDH) mutation status in adult patients with lower-grade gliomas (LGGs).
METHODS: A web-based systemic search for eligible literature up to April 13, 2021, was conducted on PubMed, Embase, and the Cochrane Library databases by two independent reviewers. This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. We included studies evaluating the accuracy of the T2-FLAIR mismatch sign in diagnosing the IDH mutation in adult patients with LGGs. The T2-FLAIR mismatch sign was defined as a T2-hyperintense lesion that is hypointense on FLAIR except for a hyperintense rim.
RESULTS: Fourteen studies (n = 1986) were finally identified. The mean age of patients in the included studies ranged from 38.5 to 56 years. The pooled area under the curve (AUC), sensitivity, and specificity were obtained for each molecular profile: IDHmut-Codel: 0.46 (95% confidence interval [CI]: 0.42-0.50), 1% (95%CI: 0-7%), and 69% (95%CI: 62-75%), respectively; IDHmut-Noncodel: 0.75 (95%CI: 0.71-0.79), 42% (95%CI: 34-50%), and 99% (95%CI: 96-100%), respectively; IDH-Mutation regardless of 1p/19q codeletion status: 0.77 (95%CI: 0.73-0.80), 29% (95%CI: 21-40%), and 99% (95%CI: 92-100%), respectively.
CONCLUSIONS: The T2-FLAIR mismatch sign was an insensitive but highly specific marker for IDHmut-Noncodel and IDH-Mutation LGGs, whereas it was not a useful marker for IDHmut-Codel LGGs. The findings might identify the T2-FLAIR mismatch sign as a non-invasive imaging biomarker for the selection of patients with IDH-mutant LGGs.
KEY POINTS: • The T2-FLAIR mismatch sign was not a sensitive sign for IDH mutation in LGGs. • The T2-FLAIR mismatch sign was related to IDHmut-Noncodel with a specificity of 99%. • The pooled specificity (69%) of the T2-FLAIR mismatch sign for IDHmut-Codel was low.
引用
- Han, Chen, Zhang, et al. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis. Eur Radiol. 2022. PMID: 35169897. doi:10.1007/s00330-022-08607-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。